Literature DB >> 30289735

LI-RADS Version 2018 Ancillary Features at MRI.

Milena Cerny1, Victoria Chernyak1, Damien Olivié1, Jean-Sébastien Billiard1, Jessica Murphy-Lavallée1, Ania Z Kielar1, Khaled M Elsayes1, Laurence Bourque1, Jonathan C Hooker1, Claude B Sirlin1, An Tang1.   

Abstract

The Liver Imaging Reporting and Data System (LI-RADS) standardizes performance of liver imaging in patients at risk for hepatocellular carcinoma (HCC) as well as interpretation and reporting of the results. Developed by experts in liver imaging and supported by the American College of Radiology, LI-RADS assigns to observations categories that reflect the relative probability of benignity, HCC, or other malignancy. While category assignment is based mainly on major imaging features, ancillary features may be applied to improve detection and characterization, increase confidence, or adjust LI-RADS categories. Ancillary features are classified as favoring malignancy in general, HCC in particular, or benignity. Those favoring malignancy in general or HCC in particular may be used to upgrade by a maximum of one category up to LR-4; those favoring benignity may be used to downgrade by a maximum of one category. If there are conflicting ancillary features (ie, one or more favoring malignancy and one or more favoring benignity), the category should not be adjusted. Ancillary features may be seen at diagnostic CT, MRI performed with extracellular agents, or MRI performed with hepatobiliary agents, with the exception of one ancillary feature assessed at US. This article focuses on LI-RADS version 2018 ancillary features seen at MRI. Specific topics include rules for ancillary feature application; definitions, rationale, and illustrations with clinical MRI examples; summary of evidence and diagnostic performance; pitfalls; and future directions. ©RSNA, 2018.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30289735     DOI: 10.1148/rg.2018180052

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  19 in total

1.  Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients.

Authors:  Anna Darnell; Jordi Rimola; Ernest Belmonte; Enric Ripoll; Ángeles Garcia-Criado; Carla Caparroz; Álvaro Díaz-González; Ramón Vilana; María Reig; Carmen Ayuso; Jordi Bruix; Alejandro Forner
Journal:  Eur Radiol       Date:  2021-01-06       Impact factor: 5.315

Review 2.  Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance.

Authors:  Julie Y An; Miguel A Peña; Guilherme M Cunha; Michael T Booker; Bachir Taouli; Takeshi Yokoo; Claude B Sirlin; Kathryn J Fowler
Journal:  Radiographics       Date:  2020 Nov-Dec       Impact factor: 5.333

3.  The impeded diffusion fraction quantitative imaging assay demonstrated in multi-exponential diffusion phantom and prostate cancer.

Authors:  Dariya I Malyarenko; Scott D Swanson; Sean D McGarry; Peter S LaViolette; Thomas L Chenevert
Journal:  Magn Reson Med       Date:  2021-11-14       Impact factor: 4.668

4.  LI-RADS ancillary features favoring benignity: is there a role in LR-5 observations?

Authors:  Roberto Cannella; Federica Vernuccio; Michela Antonucci; Domenico Salvatore Gagliano; Francesco Matteini; Massimo Midiri; Giuseppe Brancatelli
Journal:  Eur Radiol       Date:  2021-09-20       Impact factor: 7.034

5.  Interrater reliability and agreement of the liver imaging reporting and data system (LI-RADS) v2018 for the evaluation of hepatic lesions.

Authors:  Ahmed S Abdelrahman; Sherihan S Madkour; Mena E Y Ekladious
Journal:  Pol J Radiol       Date:  2022-06-13

6.  Evaluation of non-contrast magnetic resonance imaging as an imaging surveillance tool for hepatocellular carcinoma in at-risk patients.

Authors:  Jing Kai Joel Liu; Chau Hung Lee; Cher Heng Tan
Journal:  Singapore Med J       Date:  2020-08-17       Impact factor: 3.331

Review 7.  Overview of spontaneous intraabdominal tumor hemorrhage: etiologies, imaging findings, and management.

Authors:  Kevin Kalisz; Michael Enzerra; Bahar Mansoori
Journal:  Abdom Radiol (NY)       Date:  2020-07-20

8.  Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.

Authors:  Lin Sun; Luwen Mu; Jing Zhou; Wenjie Tang; Linqi Zhang; Sidong Xie; Jingbiao Chen; Jin Wang
Journal:  Cancer Immunol Immunother       Date:  2021-05-16       Impact factor: 6.968

9.  Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.

Authors:  Sang Min Lee; Jeong Min Lee; Su Joa Ahn; Hyo Jin Kang; Hyun Kyung Yang; Jeong Hee Yoon
Journal:  Korean J Radiol       Date:  2021-03-09       Impact factor: 3.500

Review 10.  CT/MRI LI-RADS v2018 vs. CEUS LI-RADS v2017-Can Things Be Put Together?

Authors:  Cosmin Caraiani; Bianca Boca; Vlad Bura; Zeno Sparchez; Yi Dong; Christoph Dietrich
Journal:  Biology (Basel)       Date:  2021-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.